Viral Hepatitis Differential Diagnoses

1. Wasley A, Grytdal S, Gallagher K, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ. 2008 Mar 21. 57(2):1-24. [QxMD MEDLINE Link]. [Full Text].

2. Previsani N, Lavanchy D, World Health Organization. Hepatitis B (WHO/CDS/CSR/LYO/2002.2). 2002. [Full Text].

3. Fattovich G. Natural history of hepatitis B. J Hepatol. 2003. 39 suppl 1:S50-8. [QxMD MEDLINE Link]. [Full Text].

4. [Guideline] Terrault NA, Bzowej NH, Chang KM, et al, for the American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan. 63(1):261-83. [QxMD MEDLINE Link]. [Full Text].

5. [Guideline] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015 Mar. [QxMD MEDLINE Link]. [Full Text].

6. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006. 3(2):47-52. [QxMD MEDLINE Link]. [Full Text].

7. [Guideline] Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020 Feb. 71(2):686-721. [QxMD MEDLINE Link]. [Full Text].

8. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006 Oct. 45(4):529-38. [QxMD MEDLINE Link].

9. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance United States, 2014 (revised: 9/26/16). Available at https://www.cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014hepsurveillancerpt.pdf. Accessed: June 12, 2017.

10. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008 Dec. 6(12):1315-41; quiz 1286. [QxMD MEDLINE Link]. [Full Text].

11. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009 May. 49(5 suppl):S4-S12. [QxMD MEDLINE Link].

12. [Guideline] Lok AS, McMahon BJ. AASLD practice guideline update: chronic hepatitis B: update 2009. Hepatology. 2009 Sep. 50(3):661-2. [QxMD MEDLINE Link]. [Full Text].

13. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004 Feb. 2(2):87-106. [QxMD MEDLINE Link].

14. Tabor E. The role of tumor suppressor genes in the development of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York, NY: Churchill Livingstone; 1997. 89-95.

15. Chen CJ, Yang HI, Iloeje UH, for the REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009 May. 49(5 suppl):S72-84. [QxMD MEDLINE Link].

16. Liaw YF, Sung JJ, Chow WC, et al, for the Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7. 351(15):1521-31. [QxMD MEDLINE Link]. [Full Text].

17. Di Marco V, Marzano A, Lampertico P, et al, for the Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004 Oct. 40(4):883-91. [QxMD MEDLINE Link]. [Full Text].

18. World Health Organization. Hepatitis C. Fact sheet no 164. Available at http://www.who.int/mediacentre/factsheets/fs164/en/. Updated: April 2017; Accessed: June 12, 2017.

19. Centers for Disease Control and Prevention. Viral hepatitis: hepatitis C FAQs for health professionals. Available at https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Updated: January 27, 2017; Accessed: June 12, 2017.

20. [Guideline] World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection: updated version (April 2016). 2016 Apr. [QxMD MEDLINE Link]. [Full Text].

21. World Health Organization. Hepatitis E. Fact sheet no 280. Available at http://www.who.int/mediacentre/factsheets/fs280/en/. Updated: July 2016; Accessed: June 13, 2017.

22. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet. 2004 Jun. 85(3):240-4. [QxMD MEDLINE Link].

23. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008 Feb 21. 358(8):811-7. [QxMD MEDLINE Link]. [Full Text].

24. Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med. 2008 Feb 21. 358(8):859-60. [QxMD MEDLINE Link]. [Full Text].

25. Kamar N, Mansuy JM, Cointault O, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant. 2008 Aug. 8(8):1744-8. [QxMD MEDLINE Link]. [Full Text].

26. Centers for Disease Control and Prevention. Viral hepatitis. Available at https://www.cdc.gov/hepatitis/abc/index.htm. Updated: May 26, 2016; Accessed: June 13, 2017.

27. World Health Organization. Hepatitis A. Fact sheet no 328. Available at http://www.who.int/mediacentre/factsheets/fs328/en/. Updated: July 2016; Accessed: June 12, 2017.

28. Centers for Disease Control and Prevention. Hepatitis A questions and answers for health professionals. Available at https://www.cdc.gov/hepatitis/hav/havfaq.htm. Updated: July 13, 2016; Accessed: June 13, 2017.

29. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis – United States, 2015 (updated: May 11, 2017). Available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm. Accessed: June 12, 2017.

30. World Health Organization. Hepatitis B. Fact sheet no 204. Available at http://www.who.int/mediacentre/factsheets/fs204/en/. Updated: April 2017; Accessed: June 12, 2017.

31. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct 8. 461(7265):798-801. [QxMD MEDLINE Link]. [Full Text].

32. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17. 461(7262):399-401. [QxMD MEDLINE Link].

33. World Health Organization. Hepatitis D. Fact sheet. Available at https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-d. July 2016; Accessed: June 12, 2017.

34. Adhami T, Levinthal G. Hepatitis E and hepatitis G/GBV-C. The Cleveland Clinic Disease Management Project. May 29, 2002.

35. Previsani N, Lavanchy D, World Health Organization. Hepatitis E (WHO/CDS/CSR/EDC/2001.12.). 2001.

36. Chivero ET, Stapleton JT. Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. J Gen Virol. 2015 Jul. 96(pt 7):1521-32. [QxMD MEDLINE Link]. [Full Text].

37. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10. 388(10049):1081-8. [QxMD MEDLINE Link]. [Full Text].

38. World Health Organization. World hepatitis day: 28 July. Hepatitis A & E. 2014. Available at http://www.who.int/campaigns/hepatitis-day/2014/hepatitis-a-e.pdf?ua=1. Accessed: June 12, 2017.

39. Thomas E, Yoneda M, Schiff ER. Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med. 2015 Feb 2. 5(2):a021345. [QxMD MEDLINE Link]. [Full Text].

40. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011 Aug 13. 378(9791):571-83. [QxMD MEDLINE Link]. [Full Text].

41. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar. 11(2):97-107. [QxMD MEDLINE Link].

42. National Heart, Lung, and Blood Institute. What are the risks of a blood transfusion?. Available at https://www.nhlbi.nih.gov/health/health-topics/topics/bt/risks. Updated: January 30, 2012; Accessed: June 12, 2017.

43. Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention (CDC) 2008-2015 (updated: July 14, 2016). Available at https://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm. Accessed: June 12, 2017.

44. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997 Sep. 26(3 suppl 1):62S-65S. [QxMD MEDLINE Link].

45. Krawitt EL. Autoimmune hepatitis: classification, heterogeneity, and treatment. Am J Med. 1994 Jan 17. 96(1A):23S-26S. [QxMD MEDLINE Link].

46. Koneru A, Nelson N, Hariri S, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission - United States and Kentucky, 2011-2014. MMWR Morb Mortal Wkly Rep. 2016 Jul 22. 65(28):705-10. [QxMD MEDLINE Link]. [Full Text].

47. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology. 1997 Sep. 26(3 suppl 1):66S-70S. [QxMD MEDLINE Link].

48. Adhami T, Levinthal G. Hepatitis D. The Cleveland Clinic Disease Management Project. May 29, 2002.

49. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014 Jan. 16(1):365. [QxMD MEDLINE Link]. [Full Text].

50. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015 Sep. 63(3):586-92. [QxMD MEDLINE Link]. [Full Text].

51. Sultanik P, Pol S. Hepatitis delta virus: epidemiology, natural course and treatment. J Infect Dis Ther. 2016 Mar 3. 4:271. [Full Text].

52. Khuroo MS, Kamili S, Khuroo MS. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. J Viral Hepat. 2009 Jul. 16(7):519-23. [QxMD MEDLINE Link].

53. Mathur P, Arora NK, Panda SK, Kapoor SK, Jailkhani BL, Irshad M. Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. Indian Pediatr. 2001 May. 38(5):461-75. [QxMD MEDLINE Link].

54. Previsani N, Lavanchy D, World Health Organization. Hepatitis C (WHO/CDS/CSR/LYO/2003). 2002.

55. Previsani N, Lavanchy D, World Health Organization. Hepatitis D (WHO/CDS/CSR/NCS/2001.1). 2001.

56. Smith BD, Morgan RL, Beckett GA, et al, for the Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17. 61(RR-4):1-32. [QxMD MEDLINE Link]. [Full Text].

57. Waknine Y. FDA approves first rapid HCV test. Medscape Medical News. June 28, 2010. Available at http://www.medscape.com/viewarticle/724236. Accessed: June 30, 2010.

58. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr. 134(4):960-74. [QxMD MEDLINE Link]. [Full Text].

59. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014 Feb. 16(2):372. [QxMD MEDLINE Link].

60. Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015 Jan. 13(1):27-36. [QxMD MEDLINE Link]. [Full Text].

61. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995 Dec. 19 (12):1409-17. [QxMD MEDLINE Link].

62. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004 Dec. 24 (6):547-51. [QxMD MEDLINE Link].

63. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998 Jun. 93 (6):896-900. [QxMD MEDLINE Link].

64. Janssen HL, van Zonneveld M, Senturk H, et al, for the HBV 99-01 Study Group, Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005 Jan 8-14. 365 (9454):123-9. [QxMD MEDLINE Link].

65. Lau GK, Piratvisuth T, Luo KX, et al, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30. 352 (26):2682-95. [QxMD MEDLINE Link].

66. Marcellin P, Lau GK, Bonino F, et al, for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004 Sep 16. 351 (12):1206-17. [QxMD MEDLINE Link].

67. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009 May. 49 (5 suppl):S112-21. [QxMD MEDLINE Link].

68. Brouwer WP, Xie Q, Sonneveld MJ, et al, for the ARES Study Group. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology. 2015 May. 61(5):1512-22. [QxMD MEDLINE Link]. [Full Text].

69. Marcellin P, Ahn SH, Ma X, et al, for the Study 149 Investigators. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016 Jan. 150(1):134-44.e10. [QxMD MEDLINE Link]. [Full Text].

70. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006 Sep. 44(3):675-84. [QxMD MEDLINE Link]. [Full Text].

71. [Guideline] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr. 67 (4):1560-99. [QxMD MEDLINE Link]. [Full Text].

72. Jaeckel E, Cornberg M, Wedemeyer H, et al, for the German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15. 345 (20):1452-7. [QxMD MEDLINE Link].

73. Nelson DR, Davis GL, Jacobson I, et al. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol. 2009 Apr. 7 (4):397-414; quiz 366. [QxMD MEDLINE Link].

74. [Guideline] American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Simplified HCV treatment* for treatment-naive adults without cirrhosis. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. Available at https://www.hcvguidelines.org/treatment-naive/simplified-treatment. Updated: August 27, 2020; Accessed: December 9, 2021.

75. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014 Feb 8. 383(9916):515-23. [QxMD MEDLINE Link].

76. Afdhal N, Zeuzem S, Kwo P, et al, for the ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15. 370(20):1889-98. [QxMD MEDLINE Link]. [Full Text].

77. Nkuize M, Serste T, Buset M, Mulkay JP. Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Ther Clin Risk Manag. 2016. 12:861-72. [QxMD MEDLINE Link]. [Full Text].

78. Feld JJ, Jacobson IM, Hezode C, et al, for the ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015 Dec 31. 373(27):2599-607. [QxMD MEDLINE Link]. [Full Text].

79. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015 Dec 1. 163(11):818-26. [QxMD MEDLINE Link].

80. Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol. 2018 Sep. 69(3):603-7. [QxMD MEDLINE Link]. [Full Text].

81. Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017. 11:497-502. [QxMD MEDLINE Link]. [Full Text].

82. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018 Jan 25. 378(4):354-69. [QxMD MEDLINE Link]. [Full Text].

83. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Oct. 17(10):1062-8. [QxMD MEDLINE Link].

84. Xu HQ, Wang CG, Xiao P, Gao YH. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C patients: a systematic review and meta-analysis. J Clin Transl Hepatol. 2020 Sep 28. 8(3):267-76. [QxMD MEDLINE Link]. [Full Text].

85. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016 Jan 1. 62(1):32-6. [QxMD MEDLINE Link].

86. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015 Jul 7. 163(1):1-13. [QxMD MEDLINE Link].

87. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24. 370(17):1594-603. [QxMD MEDLINE Link]. [Full Text].

88. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015 May. 49(5):566-81. [QxMD MEDLINE Link].

89. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22. 370(21):1973-82. [QxMD MEDLINE Link]. [Full Text].

90. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006 Sep. 44 (3):713-20. [QxMD MEDLINE Link].

91. Bourliere M, Gordon SC, Flamm SL, et al, for the POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017 Jun 1. 376(22):2134-46. [QxMD MEDLINE Link]. [Full Text].

92. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15. 384(9956):1756-65. [QxMD MEDLINE Link].

93. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al, for the AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16. 370(3):211-21. [QxMD MEDLINE Link]. [Full Text].

94. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995 Oct 21. 346 (8982):1051-5. [QxMD MEDLINE Link].

95. Bruno S, Stroffolini T, Colombo M, et al, for the Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007 Mar. 45 (3):579-87. [QxMD MEDLINE Link].

96. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000 Nov. 32(5):1131-7. [QxMD MEDLINE Link].

97. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008 Sep 16. 149 (6):399-403. [QxMD MEDLINE Link].

98. Da BL, Lourdusamy V, Kushner T, Dieterich D, Saberi B. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. Eur J Gastroenterol Hepatol. 2021 Jun 1. 33(6):859-61. [QxMD MEDLINE Link].

99. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999 Aug. 30 (2):546-9. [QxMD MEDLINE Link].

100. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008 Apr. 15 (4):314-21. [QxMD MEDLINE Link].

101. Fiore AE, Wasley A, Bell BP, for the Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006 May 19. 55(RR-7):1-23. [QxMD MEDLINE Link]. [Full Text].

102. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998 Jan 29. 338(5):286-90. [QxMD MEDLINE Link]. [Full Text].

103. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med. 2009 Jan 6. 150 (1):40-4. [QxMD MEDLINE Link].

104. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007 Oct 19. 56 (41):1080-4. [QxMD MEDLINE Link].

105. Centers for Disease Control and Prevention. Hepatitis B FAQs for health professionals. Available at https://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#recctbl. Updated: August 4, 2016; Accessed: June 13, 2017.

106. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine. 2012 Mar 28. 30(15):2556-63. [QxMD MEDLINE Link].

107. Chang MH, Chen TH, Hsu HM, et al, for the Taiwan Childhood HCC Study Group. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005 Nov 1. 11 (21):7953-7. [QxMD MEDLINE Link].

108. Moorman AC, de Perio MA, Goldschmidt R, et al. Testing and clinical management of health care personnel potentially exposed to hepatitis C virus - CDC guidance, United States, 2020. MMWR Recomm Rep. 2020 Jul 24. 69(6):1-8. [QxMD MEDLINE Link]. [Full Text].

109. McHutchison JG, Dusheiko G, Shiffman ML, et al, for the TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29. 357 (22):2227-36. [QxMD MEDLINE Link].

110. Centers for Disease Control and Prevention. HIV and viral hepatitis. Available at https://www.cdc.gov/hiv/pdf/library/factsheets/hiv-viral-hepatitis.pdf. June 2017; Accessed: June 13, 2017.

111. Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016 Jan. 63 (1):319-33. [QxMD MEDLINE Link].

Naga Swetha Samji, MD Physician, Bellin Clinic, Bellin Health Systems

Naga Swetha Samji, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, Wisconsin Medical Society

Disclosure: Nothing to disclose.

Adrienne M Buggs, MD, FACEP, FAAEM Medical Policy Advisor, Office of Merchant Mariner Credentialing, United States Coast Guard

Adrienne M Buggs, MD, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

Praveen K Roy, MD, MSc Clinical Assistant Professor of Medicine, University of New Mexico School of Medicine

Praveen K Roy, MD, MSc is a member of the following medical societies: Alaska State Medical Association, American Gastroenterological Association

Disclosure: Nothing to disclose.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Eugene Hardin, FAAEM, FACEP Former Chair and Associate Professor, Department of Emergency Medicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine, Martin Luther King Jr/Drew Medical Center

Disclosure: Nothing to disclose.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Joseph K Lim, MD Associate Professor of Medicine, Director, Yale Viral Hepatitis Program, Section of Digestive Diseases, Yale University School of Medicine

Joseph K Lim, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Robert M McNamara, MD, FAAEM Chair and Professor, Department of Emergency Medicine, Temple University School of Medicine

Robert M McNamara, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Medical Association, Pennsylvania Medical Society, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajeev Vasudeva, MD, FACG Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Rajeev Vasudeva, MD, FACG is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Columbia Medical Society, South Carolina Gastroenterology Association, and South Carolina Medical Association

Disclosure: Pricara Honoraria Speaking and teaching; UCB Consulting fee Consulting

David C Wolf, MD, FACP, FACG, AGAF Medical Director of Liver Transplantation, Westchester Medical Center; Professor of Clinical Medicine, Division of Gastroenterology and Hepatobiliary Diseases, Department of Medicine, New York Medical College

David C Wolf, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, and American Gastroenterological Association

Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article